Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([ 11 C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [ 11 C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.
INTRODUCTION
Angiogenesis is a critical component for growth and metastatic spread of tumors (Hanahan and Weinberg, 2000; Carmeliet, 2000) . Vascular endothelial growth factor (VEGF), which is overexpressed in many human malignancies, is a key regulator of tumor angiogenesis, inducing proliferation, differentiation, and migration of endothelial cells (Ferrara et al., 2003) . Consequently, numerous drugs have been developed to target the signaling pathways of VEGF and its receptors (VEGFR; Ferrara and Kerbel, 2005) .
Bevacizumab is a humanized monoclonal antibody that targets circulating VEGF and subsequently prevents binding of VEGF to its receptors (Ferrara et al., 2004) . Except for metastatic renal cell cancer (Yang et al., 2003) , clinical efficacy of singleagent bevacizumab treatment has been very limited in the majority of advanced malignancies (Reese et al., 2001; Cobleigh et al., 2003) . Combined with chemotherapy, however, additional value was shown in colorectal (Hurwitz et al., 2004) , breast (Miller et al., 2007) , and non-small cell lung cancer (NSCLC; Sandler et al., 2006) .
In the past years, the normalization theory proposed by Jain (2001) has gained widespread acceptance for explaining additional antitumor effects of inhibitors of VEGF signaling, when combined with cytotoxic drugs. It is hypothesized that anti-angiogenic drugs normalize structurally and functionally abnormal tumor vasculature, thereby reducing interstitial fluid pressure, improving drug penetration, and subsequently
Significance
Optimal scheduling of anti-angiogenic drugs is important for improving efficacy of combination therapy in patients with advanced-stage cancer. In this study, effects of the anti-angiogenic drug bevacizumab on delivery of chemotherapy to non-small cell lung cancer (NSCLC) were investigated using positron emission tomography and 11 C-labeled docetaxel. Bevacizumab induced a rapid and significant reduction in delivery of chemotherapy to tumors in NSCLC patients. The study provides a framework for investigating effects of anti-angiogenic drugs on drug delivery to tumors in vivo. In addition, it highlights the importance of drug scheduling and advocates further studies to optimize scheduling of anti-angiogenic drugs.
enhancing efficacy of cytotoxic drugs. Exploration of the normalization window may be crucial for optimizing drug scheduling in order to improve clinical efficacy. To date, however, no clinical studies have been reported on the effects of anti-angiogenic agents on drug delivery in cancer patients.
Positron emission tomography (PET) is a noninvasive imaging technique that can be used to monitor drug pharmacokinetics and pharmacodynamics in vivo by radiolabeling drugs of interest with short-lived positron emitting radionuclides (Gambhir, 2002) . Previously, the cytotoxic drug docetaxel, a taxane targeting the microtubular network, has been radiolabeled with the radionuclide C-11 ([ 11 C]docetaxel; van Tilburg et al., 2004) , enabling in vivo quantification of docetaxel kinetics in lung cancer (Van der Veldt et al., 2011) . In the latter study, feasibility of noninvasive PET measurements using radiolabeled water ([ 15 The purpose of the present study was to investigate the effects of anti-angiogenic drugs on tumor perfusion and [ 11 C]docetaxel delivery in patients with advanced-stage NSCLC using PET. To this end, bevacizumab was selected, as it is the most selective inhibitor of VEGF signaling among currently approved anti-angiogenic drugs. It was hypothesized that bevacizumab improves drug delivery by normalizing tumor vasculature, which should be reflected by a more homogeneous distribution of perfusion and [ 11 C]docetaxel delivery. A secondary objective of this study was to investigate (systemic) effects of bevacizumab on (1) circulating VEGF levels in plasma; (2) cardiovascular parameters, including blood pressure, cardiac output, and microcirculation in muscle and skin; (3) systemic exposure of [ 11 C]docetaxel; and (4) perfusion and [ 11 C]docetaxel uptake in normal tissues. For the latter, the thyroid gland and the vertebral body were selected. The thyroid gland is known to be highly sensitive to VEGF inhibition (Kamba et al., 2006) , whereas the vertebral body may reflect effects of bevacizumab on [
11 C]docetaxel uptake in bone marrow. 
RESULTS

Bevacizumab Induces Rapid Reduction in Tumor Perfusion
To investigate the effect of anti-VEGF therapy on tumor perfusion (F), PET scans using
which is a freely diffusible tracer (Hoekstra et al., 2002; Wilson et al., 1992) , were performed at baseline and 2 hr, 5 hr, and 4 days after bevacizumab administration. Five hours after bevacizumab administration, there was a significant reduction in tumor perfusion, which persisted until day 4 ( Figures 1A and 2A) . In three out of eight patients, tumor perfusion already decreased 2 hr after the end of bevacizumab infusion. Accordingly, tumor perfusion showed median percentage changes of 8% (range À39 to +15%; N = 9; p value = 0.889), À20% (range, À39 to À7%; N = 8; p value = 0.012), and À38% (range, À55 to À4%; N = 10; p value = 0.005) at 2 hr, 5 hr, and 4 days after bevacizumab administration, respectively. In addition, the volume of distribution of water (V T ), a measure of the (viable) fraction of tissue that is able to exchange [ 15 O]H 2 O, was decreased at 4 days after bevacizumab administration ( Figure 1B) , with a median percentage change of À7% (range, À52 to +2%; N = 10; p value = 0.022). Individually, eight out of ten patients showed a reduction in volume of distribution of water. Although both perfusion and volume of distribution of water showed an overall decrease, the reduction in perfusion was more severe, as illustrated by a significant decrease in the ratio of tumor perfusion over volume of distribution (F/V T ; ( Figure 1C ). Collectively, these findings indicate that the decrease in tumor perfusion is not due to a reduction in tumor tissue, which was confirmed by an unchanged tumor volume on subsequent computed tomography (CT) scans. (Patlak et al., 1983; Van der Veldt et al., 2011 (Verheul et al., 1997) , circulating VEGF was assessed in both platelet-poor and platelet-rich plasma. At 3 hr, administration of bevacizumab resulted in a significant decrease in circulating VEGF in platelet-rich plasma (N = 7; p value = 0.018; Figure 3 ). In the majority of patients, free VEGF in plasma was completely neutralized within 3 hr and seemed to recover in part after 4 days. Comparable changes in VEGF levels were measured in platelet-poor plasma. (Knaapen et al., 2008) , however, showed a trend toward a reduction at day 4 (from 6.9 l$min À1 to 6.0 l$min À1 ; N = 9; p value = 0.051; Figure 4C ). As inhibitors of VEGF/VEGFR-2 signaling may induce so-called rarefaction (Mourad et al., 2008) , that is, a reduction in the number of arterioles or capillaries within vascular beds of various tissues (e.g., muscle and skin), muscle perfusion in the erector spinae, as well as capillary density in the skin, were measured. Muscle perfusion was obtained from the [
15
O]H 2 O images, whereas nailfold capillaries in the dorsal skin of the third finger were examined using a capillary microscope (Serné et al., 2001) . Perfusion in the erector spinae muscle and capillary density in the skin did not change during the first 4 days after administration of 
Bevacizumab Decreases Thyroid Perfusion
Because normal vessels of the thyroid gland are known for their extensive capillary regression after anti-VEGF therapy (Kamba et al., 2006) , thyroid perfusion was also determined using parametric perfusion images. In four out of ten patients, the primary tumor was located in the upper lobes, enabling adequate analysis of thyroid perfusion at baseline and day 4. Four days after bevacizumab administration, median perfusion in the thyroid gland showed a decrease (from 1.316 ml$cm À3 $min À1 at baseline to 0.585 ml$cm À3 $min À1 at day 4; p value = 0.068), whereas the volume of distribution of water did not change (p value = 0.273). 
DISCUSSION
Current strategies combining anti-angiogenic therapy with cytotoxic agents have shown proven efficacy in cancer patients, including those with advanced-stage NSCLC (Sandler et al., 2006) . Pretreatment with anti-angiogenic drugs may transiently normalize abnormal tumor vasculature (Batchelor et al., 2007) and thereby contribute to improved delivery of subsequent chemotherapy, enhancing efficacy (Jain, 2005) . Investigating this process of vasculature normalization in vivo is a major challenge, which is mainly restricted to imaging studies. Whereas conventional imaging studies, such as CT and magnetic resonance imaging, have concentrated on changes in tumor perfusion, the present concept of PET imaging using a radiolabeled drug to study drug delivery in patients after anti-VEGF therapy has not been reported yet. The humanized monoclonal antibody bevacizumab induced an overall decrease in both perfusion and K i of [
11 C]docetaxel in tumor tissue within a few hours after bevacizumab administration, a decrease that persisted for at least four days. These findings represent physiological changes in tumors, as measured changes were beyond the known test-retest variability (van der Veldt et al., 2010a and . The large range of changes in perfusion and [ 11 C]docetaxel uptake is most likely due to interpatient differences in tumor response to bevacizumab and partly due to differences in interval between end of bevacizumab infusion and PET scans. Nevertheless, the results indicate a decrease in perfusion and [
11 C]docetaxel uptake in tumor tissue of all patients. Based on these data, it can be concluded that anti-VEGF therapy is not able to improve drug delivery to tumors but rather has the opposite effect.
Results of the present study are at variance with those obtained by Willett et al. (2004) , where improved drug delivery in rectal cancer was postulated partly based on human imaging studies. Tumor perfusion, as determined by dynamic contrastenhanced CT scanning decreased, whereas the standardized uptake value of 2 0 -deoxy-2 a result of certain normalization of tumor vasculature. Nevertheless, these possible changes in tumor heterogeneity did not result in improved drug delivery, as bevacizumab infusion caused a rapid and overall reduction in [ 11 C]docetaxel K i in tumors. In addition, drug uptake may be further impaired by development of tumor necrosis, associated with extensive vascular damage, which usually develops after anti-VEGF therapy. Although it is not possible to define necrotic areas on low-dose CT, development of necrotic areas was possibly reflected by a reduction in the distribution volume of water after 4 days, despite an unchanged total tumor volume on low-dose CT.
Apart from tumor parameters, systemic effects after administration of bevacizumab were evaluated. The rapid changes in tumor perfusion and [ 11 C]docetaxel K i were associated with an immediate reduction in plasma levels of VEGF, indicating an immediate inhibition of VEGF signaling in the whole body. This rapid neutralization of circulating VEGF also induced a decrease in perfusion of the thyroid gland, whereas perfusion and [ 11 C]docetaxel K i in the vertebral body and muscle tissue were not affected. In addition, K i values of [ 11 C]docetaxel in the vertebral body and muscle tissue were essentially different from that in tumor tissue and were not related to perfusion in these normal tissues. These findings imply that tumor tissue shows a difference in sensitivity to VEGF inhibition (Kamba et al., 2006) and in drug delivery as compared with normal tissues. Among the cardiovascular parameters, only cardiac output showed a decrease at day 4, whereas blood pressure and capillary density did not change during the first 4 days after 11 C]docetaxel uptake in tumors is probably too rapid to be solely ascribed to inhibition of tumor angiogenesis, vasoconstrictive effects of anti-angiogenic drugs on tumor vessels, particularly those from the host, should be considered as a potential underlying mechanism. In this regard, inhibition of endothelial nitric oxide synthesis by VEGF inhibitors may be an important factor (Dhaun and Webb, 2010; Syrigos et al., 2011; Ng et al., 2007) . Although plasma clearance of [ 11 C]docetaxel decreased slightly after bevacizumab administration, signifying prolonged duration of [ 11 C]docetaxel exposure, this decrease in clearance appeared to be too limited to result in an overall increase in [ 11 C]docetaxel uptake, that is, retention index, by tumors. Bevacizumab was selected to investigate the effects of antiangiogenic agents, as it is the most selective inhibitor of VEGF signaling among presently approved anti-angiogenic drugs, and it does not have multiple targets like most tyrosine kinase inhibitors. In addition, the long terminal half-life of 17-21 days (Ferrara et al., 2004) (Sandler et al., 2006; Kudoh et al., 2006) , single-agent bevacizumab is not considered effective for the treatment of NSCLC patients. Consequently, ethically it was not acceptable to prolong the study with PET measurements at later time points. In addition, the localization of the lung tumors did not enable invasive measurements of interstitial fluid pressure (Curti et al., 1993) or sequential biopsies for additional histopathological analyses. Furthermore, use of tracer amounts of docetaxel (microdoses) may be a potential limitation of the present study, as it is conceivable that the effects of bevacizumab on [ 11 C]docetaxel delivery in tumors may not hold true for pharmacological drug concentrations. However, use of repeated therapeutic doses mixed with the radiolabeled drug, instead of microdoses, will obscure bevacizumab-induced effects, as cytotoxic drugs themselves also affect both tumor perfusion (Dunnwald et al., 2008) and interstitial fluid pressure (Griffon-Etienne et al., 1999) and may modulate the specific targets of the drug under study (Shalli et al., 2005) . In a separate study, in which [
11 C]docetaxel was given at tracer concentrations and during infusion of a therapeutic dose, albeit was possible to predict tumor uptake of (therapeutic) docetaxel from the tumor kinetics of (tracer) [ The results of the present study pose a number of important issues relevant to anti-angiogenic drugs administered in combination with other anticancer drugs. In human tumors, bevacizumab induced a rapid decrease in perfusion and [ 11 C]docetaxel uptake. It is conceivable that other inhibitors of the VEGF signaling pathways may produce similar effects. In addition, it is likely that these effects may persist during continued treatment with these drugs. Therefore, administration of anti-angiogenic drugs can be considered after administration of the other anticancer agents, as the immediate decrease in tumor perfusion should decrease clearance of drugs from tumors. Hence, preclinical studies are warranted to investigate this concept for scheduling of anticancer drugs. To improve scheduling of combination therapy, other potential mechanisms need to be investigated to understand the synergistic effects with antiangiogenic drugs. In this regard, it is important to explore the effects of anti-angiogenic drugs on proliferative activity of tumor cells (Ortholan et al., 2010) and their environment, such as mobilization of bone marrow-derived circulating endothelial progenitor cells (Shaked et al., 2008) and acute release of cytokines from the tumor microenvironment (Gilbert and Hemann, 2010) . The results of the present study may explain why several clinical trials have failed to show the additional value of antiangiogenic drugs in specific populations of cancer patients. Clearly, more clinical studies are needed to assess whether administration schedules affect response and outcome of combination strategies. To this end, the optimal design to prove clinical relevance of drug scheduling would be a randomized controlled trial in which cancer patients are randomized to different administration schedules.
In conclusion, the results of this human study indicate a rapid and significant reduction in perfusion and [
11 C]docetaxel uptake in NSCLC after administration of bevacizumab. The clinical relevance of these findings is notable, as the present study did not provide evidence for a substantial improvement in drug delivery to tumors but rather showed the opposite effect. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.
EXPERIMENTAL PROCEDURES Patient Selection
Between October 2009 and September 2010, ten patients (six men and four women; median age 58 years; range, 47-70 years) with advanced-stage NSCLC were prospectively enrolled. Patients participated in this study prior to their scheduled therapy. The study was approved by the Medical Ethics Review Committee of the VU University Medical Center, Amsterdam. All patients signed a protocol-specific informed consent form prior to study enrollment.
Inclusion criteria were the following: age R18 years; a malignant lesion R1.5 cm in diameter within the chest; life expectancy of at least 12 weeks; Eastern Cooperative Oncology Group performance status <3; R4 weeks since any prior surgery or radiotherapy; no previous acute toxicities (>1) in accordance with Common Terminology Criteria for Adverse Events v3.0 (CTCAE); adequate organ function [hemoglobin R6.0 mmol•l À1 ; absolute neutrophil count R1.5 3 10 9 /l; absolute platelet count >100 3 10 9 /l; total serum bilirubin %1.5 upper limit of normal (ULN); aspartate aminotransferase and alanine aminotransferase %2.5 x ULN (in case of liver metastases % 5 x ULN); alkaline phosphatase %2.5 x ULN; serum creatinine %1.5 ULN or creatinine clearance R60 ml•min À1 ; normal serum calcium; urine dipstick for proteinuria <2+]; and use of effective contraception. Exclusion criteria were the following: squamous lung cancer; history of R grade 2 hemoptysis; cavitary lesion; tumor invading major blood vessels; newly diagnosed and untreated central nervous system metastases; any unstable systemic disease (including but not limited to clinically significant cardiovascular disease and uncontrolled hypertension); major surgery or significant traumatic injury <28 days before study entry; prior treatment with taxanes or bevacizumab; concurrent treatment with other anticancer agents or experimental drugs; use of inhibitors or substrates of the efflux transporter ABCB1; serious nonhealing wound or ulcer; a history of documented hemorrhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use of aspirin (>325 mg per day); planned radiotherapy or major surgery; pregnancy or lactation; metal implants (e.g., pacemakers); and claustrophobia.
Study Design
Patients received a single infusion of bevacizumab (15 mg to postpone their planned chemotherapy for more than a few days. Hence, the protocol was amended and the last time point was set at day 4. Adverse events were graded in accordance with CTCAE v3.0. After the last PET-CT study, patients started with their scheduled therapy. In accordance with the guidelines of the Medical Ethics Review Committee of the VU University Medical Center, the total radiation burden of the study was estimated at <10 mSv.
As efficacy was not an endpoint of the present study, response evaluation and data collection for survival were not performed.
Synthesis of Radiopharmaceuticals
The radiosyntheses of [ 15 O]H 2 O and [ 11 C]docetaxel were performed in accordance with good manufacturing practice (GMP) standards (Jackson et al., 1993; van Tilburg et al., 2004 and . Docetaxel, obtained from Green PlantChem Company (Hangzhou, China), was chemically modified and used as precursor in the synthesis of [ 11 C]docetaxel.
11
C-labeled docetaxel was obtained with an isolated decay-corrected radiochemical yield of 10 ± 2% and a radiochemical purity of >98%. 
Scanning Protocol
Imaging studies were performed on a state-of-the-art three-dimensional (3D) PET-CT scanner (Gemini TF-64, Philips Medical Systems, Best, The Netherlands; Surti et al., 2007) . This scanner has an axial field of view of 18 cm, divided into 45 contiguous planes. times from the end of the bevacizumab infusion to the first, second, and third scan sessions were 1.9 hr (range, 1.4-2.3 hr), 5.6 hr (range, 4.9-8.6 hr), and 4 days (range, 3-5 days). Sudden technical difficulties, clinical problems, and logistic issues were the reasons for missing scans and different time intervals. Until 3 hr prior to scanning, food and drinks were allowed. On the day of a PET study, patients were asked to consume similar meals prior to scanning. All patients received two venous catheters, one for tracer injection and the other for blood sampling. Patients were positioned supine on the scanner bed, with both tumor and aortic arch located inside the axial field of view of the scanner. Elastic body-restraining bandages were used to minimize movement during scanning.
A 10 min dynamic scan was started simultaneously with an intravenous injection of 370 MBq [ Data were normalized and all appropriate corrections for dead time, decay, randoms, scatter, and attenuation were applied. Using the 3D row action maximum likelihood reconstruction algorithm, 1x10, 8x5, 4x10, 2x15, 3x20, 2x30, and 6x60 s) and 36 (1x10, 8x5, 4x10, 2x15, 3x20, 2x30, 6x60, 4x150 , 4x300, and 2x600 s) frames, respectively.
Blood Sampling
Sequential blood samples were collected in ACD vacutainers (8.5 ml, Becton Dickinson, Heidelberg, Germany; Cat. No. 364606) at baseline, and at 3 hr and 4 days after the end of the bevacizumab infusion. Prior to each sample, 3 ml-5 ml blood was discarded and the line was flushed with 2 ml saline after each sample. After collection, the blood samples were centrifuged immediately to obtain platelet-rich plasma (15 min; 20 C; 156 x g; N = 7 patients).
Platelet-rich plasma was further centrifuged to obtain platelet-poor plasma (15 min; 20 C; 330 x g; N = 3 patients). Thereafter, plasma was stored at À20 C until analysis. Concentrations of VEGF (pg•ml À1 ) were assessed in duplicate using a Quantikine enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, Minnesota). Vascular endothelial growth factor concentrations in platelet-rich plasma were corrected for platelet count and were expressed in pg$ml À1 per 200,000 platelets$ml
À1
.
After intravenous injection of [
11 C]docetaxel, 10 ml discrete venous samples were collected manually at 2. 5, 5, 10, 15, 20, 30, 40 , and 60 min post-injection. Blood samples were analyzed for radioactivity concentrations in blood and plasma. Whole blood (0.5 ml) was weighted in duplicate and 0.05 ml 10% Triton X-100 solution was added. After centrifuging the remaining whole blood (5 min; room temperature; 4000 rpm), plasma was harvested and 0.5 ml plasma was weighted in duplicate, again adding 0.05 ml 10% Triton X-100 solution. A well-counter, cross-calibrated against the PET scanner, was used to determine activity concentrations. Samples were not analyzed for radiolabeled metabolites, as these were not detected previously (Van der Veldt et al., 2011) .
Input Functions
Kinetic analyses of data were performed using dedicated programs written within the software environment Matlab (The MathWorks Inc., Natick, Massachusetts et al., 2010a and 2011) . Volumes of interest (VOI) of 1 cm diameter were drawn over the ascending aorta in approximately ten consecutive image planes of the frame in which the first pass of the bolus was best visualized. Projection of these VOIs onto all image frames yielded the arterial time-activity curve (TAC) C A (t). A similar approach was used for the pulmonary artery in approximately five consecutive planes, thereby providing a TAC for the pulmonary circulation C V (t) (van der Veldt et al., 2010a) . The [ 11 C]docetaxel plasma IDIF was obtained by multiplying C A (t) with a sigmoid function (Gunn et al., 1998) , which was obtained by fitting the plasma/whole blood ratios derived from the venous samples. As the rapid [ 11 C]docetaxel clearance precludes reliable input functions at later time points, the generation of input functions of [ 11 C]docetaxel was limited to the first 10 min of data (Van der Veldt et al., 2011) .
Analysis of Perfusion and [
11 C]docetaxel Kinetics in Tumors Scans were anonymized and randomly presented to an experienced observer (I.B.) who was blinded to patients' history and outcome. To delineate comparable tumor VOIs, this observer analyzed all scans from one patient in the same session. Low-dose CT images were converted to ECAT 7 format. Thereafter, primary tumors were delineated on low-dose CT images using the CAPP software package (CTI/Siemens, Knoxville, Tennessee To analyze heterogeneity of tumor perfusion at the voxel level, parametric perfusion images were generated (van der Veldt et al., 2010a) . Hence, IDIFs and a basis function implementation of the standard single-tissue compartment model were applied (Boellaard et al., 2005; Lodge et al., 2000; Watabe et al., 2005) . Fifty logarithmically spaced, precomputed basis functions with F/V T values, ranging from 0.1 to 2.0 min À1 were used and parametric perfusion images were postsmoothed with a Gaussian filter of 10 mm full width at half maximum. Then, VOIs previously defined on the low-dose CT scans were projected onto the parametric perfusion images. Next, voxel intensity histograms were generated for the whole VOI, its center and its rim. A voxel was considered to be part of the rim if at least one of the voxels in its 3D six-connected neighborhood was outside the defined VOI. In accordance with this method, the median baseline volume of the whole tumor VOI was 13. (Knaapen et al., 2008) :
where the injected radioactivity (ID) of [ 15 O]H 2 O is divided by the area under the curve of the blood activity in the pulmonary artery (C V ) multiplied by the duration of the first pass of the bolus. The TAC of the pulmonary artery was fitted with a linear upslope and followed by an exponential downslope, which was extrapolated to remove contamination of recirculating radioactivity.
Microcirculation in the Skin
In eight patients, microcirculation in the skin was investigated. At baseline, 3 hr and 4 days, nailfold capillaries in the dorsal skin of the third finger were visualized using a capillary microscope (Serné et al., 2001) . Capillary density was defined as the number of erythrocyte-perfused capillaries$mm À2 . First, baseline capillary density was recorded for 2 min. Thereafter, venous occlusion was applied to expose a maximal number of perfused capillaries.
To this end, a digital cuff was inflated to 60 mmHg for 60 s. Recordings were presented randomly and in a blind fashion to an experienced investigator (M.P.d.B.), who counted number of capillaries off-line from a videotape. Using the same visual fields as used during baseline measurements, peak capillary density during venous congestion was counted in the 60 s recordings. Dayto-day variation of baseline capillary density and peak capillary density during venous congestion were 2.3% ± 1.8% (Serné et al., 2002) and 9.5 ± 7.1% (Serné et al., 2001) , respectively.
Muscle Perfusion
On the low-dose CT scans, VOIs (diameter, 1 cm) were drawn over the erector spinae muscle in five consecutive image planes. Projection of these muscle VOIs onto the dynamic images of the corresponding [ 
where C T (t) is the total measured tissue signal in tumor as function of time, F is perfusion, V A is arterial blood volume, and V T is the volume of distribution or partition coefficient of water. To evaluate [ 11 C]docetaxel kinetics in normal tissue, muscle VOIs were also projected onto the corresponding [ 11 C]docetaxel image and those TACs were analyzed using the Patlak method (Patlak et al., 1983) . 
where the injected dose (ID) of [ 11 C]docetaxel is divided by the integral of the plasma (C P ) TAC multiplied by the body surface area.
Thyroid Perfusion
In those cases in which the thyroid gland was in the field of view, additional parametric perfusion images were generated, using 50 precomputed basis functions with F/V T values, ranging from 0.1 to 15 min À1 and postsmoothing with a Gaussian filter of 10 mm in full width at half maximum. Then, the thyroid gland could be delineated on parametric perfusion images applying a semiautomatic threshold technique (50% of the maximum voxel value with correction for local background; van der Veldt et al., 2010a Equation 2 was applied to calculate vertebral body perfusion, whereas the Patlak method (Patlak et al., 1983 ) was applied to determine [ 11 C]docetaxel uptake.
Statistics
Statistical analysis was performed using SPSS software (SPSS for Windows 16.0, SPSS, Inc., Chicago, IL). Correlations were explored using the Spearman's correlation coefficient. The Mann-Whitney test was used to compare between groups. The Wilcoxon signed-rank test was used to compare variables at 2 hr, 3 hr, 5 hr, and 4 days after bevacizumab administration with baseline values. A two-tailed probability value of p value < 0.05 was considered significant.
